前三季度营收重返“10亿元俱乐部” 广誉远加快推进精品中药全产业链升级

Core Insights - Guangyuyuan Traditional Chinese Medicine Co., Ltd. reported a total revenue of 1.061 billion yuan for the first three quarters of 2023, marking an 18.71% year-on-year increase, and a net profit attributable to shareholders of 78.884 million yuan, up 11.16% year-on-year, returning to the "10 billion club" for the first time since 2018 [1] Financial Performance - The company achieved a total revenue of 1.061 billion yuan in the first three quarters of 2023, with a year-on-year growth of 18.71% [1] - The net profit attributable to shareholders was 78.884 million yuan, reflecting an 11.16% increase compared to the previous year [1] - After excluding a one-time tax payment of 29.67 million yuan, the actual net profit for the third quarter was approximately 31.7 million yuan, representing a year-on-year increase of about 179% [1] Brand and Product Development - Guangyuyuan's core products, including Gui Ling Ji, Ding Kun Dan, and An Gong Niu Huang Wan, have been recognized as national intangible cultural heritage [1] - The company is actively promoting its Gui Ling Ji liquor, which has seen significant sales growth, with over 103,000 boxes sold, making it the second-best-selling product [2] - The company has implemented various marketing strategies, including brand exposure through high-speed rail and promotional events, to enhance product visibility and expand sales channels [2] Strategic Direction - The company aims to maintain a growth trend through its "Four Legs and Two Wings" strategy, focusing on core products while exploring potential product lines [3] - Key strategies include positioning Gui Ling Ji as a symbol of anti-aging, Ding Kun Dan for women's health, and leveraging traditional production methods for An Gong Niu Huang Wan [3] - Guangyuyuan plans to enhance its entire industry chain, innovate marketing models, and improve its competitive edge in the traditional Chinese medicine sector [3]